Literature DB >> 20373765

Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.

Long Ye1, John M Knapp, Panjamaporn Sangwung, James C Fettinger, A S Verkman, Mark J Kurth.   

Abstract

Deletion of phenylalanine residue 508 (DeltaF508) in the cystic fibrosis (CF) transmembrane conductance regulator protein (CFTR) is a major cause of CF. Small molecule "correctors" of defective DeltaF508-CFTR cellular processing hold promise for CF therapy. We previously identified and characterized bithiazole CF corrector 1 and s-cis-locked bithiazole 2. Herein, we report the regiodivergent synthesis of Ngamma and Nbeta isomers of thiazole-tethered pyrazoles with improved hydrophilicity compared to bithiazoles. We synthesized a focused library of 54 pyrazolylthiazoles 3, which included examples of both regioisomers 4 and 5. The thiazole-tethered pyrazoles allowed incorporation of property-modulating functionality on the pyrazole ring (ester, acid, and amide) while retaining DeltaF508-CFTR corrector activity (EC(50)) of under 1 microM. The most active pyrazolylthiazole (14h) has an experimentally determined log P of 4.1, which is 1.2 log units lower than bithiazole CF corrector 1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373765      PMCID: PMC3109609          DOI: 10.1021/jm100235h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors.

Authors:  Jürgen Dinges; Irini Akritopoulou-Zanze; Lee D Arnold; Teresa Barlozzari; Peter F Bousquet; George A Cunha; Anna M Ericsson; Nobuhiko Iwasaki; Michael R Michaelides; Nobuo Ogawa; Kathleen M Phelan; Paul Rafferty; Thomas J Sowin; Kent D Stewart; Ryukou Tokuyama; Zhiren Xia; Henry Q Zhang
Journal:  Bioorg Med Chem Lett       Date:  2006-06-05       Impact factor: 2.823

2.  Development of reliable aqueous solubility models and their application in druglike analysis.

Authors:  Junmei Wang; George Krudy; Tingjun Hou; Wei Zhang; George Holland; Xiaojie Xu
Journal:  J Chem Inf Model       Date:  2007-06-15       Impact factor: 4.956

3.  Physicochemical profiling: overview of the screens.

Authors:  E H Kerns; L Di
Journal:  Drug Discov Today Technol       Date:  2004-12

Review 4.  Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships.

Authors:  T Braumann
Journal:  J Chromatogr       Date:  1986-11-14

5.  1,3-diketones from acid chlorides and ketones: a rapid and general one-pot synthesis of pyrazoles.

Authors:  Stephen T Heller; Swaminathan R Natarajan
Journal:  Org Lett       Date:  2006-06-22       Impact factor: 6.005

Review 6.  Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator.

Authors:  W R Skach
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

7.  Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments.

Authors:  M Sharma; M Benharouga; W Hu; G L Lukacs
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

8.  Synthesis and biological activities of novel pyrazole oxime derivatives containing a 2-chloro-5-thiazolyl moiety.

Authors:  Hong Dai; Yong-Qiang Li; Ding Du; Xue Qin; Xin Zhang; Hai-Bo Yu; Jian-Xin Fang
Journal:  J Agric Food Chem       Date:  2008-11-26       Impact factor: 5.279

9.  Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy.

Authors:  Gui Jun Yu; Choong L Yoo; Baoxue Yang; Michael W Lodewyk; Liping Meng; Tamer T El-Idreesy; James C Fettinger; Dean J Tantillo; A S Verkman; Mark J Kurth
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

10.  A mouse model for the delta F508 allele of cystic fibrosis.

Authors:  B G Zeiher; E Eichwald; J Zabner; J J Smith; A P Puga; P B McCray; M R Capecchi; M J Welsh; K R Thomas
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  12 in total

1.  ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.

Authors:  Long Ye; Bao Hu; Faris El-Badri; Brandi M Hudson; Puay-Wah Phuan; A S Verkman; Dean J Tantillo; Mark J Kurth
Journal:  Bioorg Med Chem Lett       Date:  2014-10-02       Impact factor: 2.823

2.  Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.

Authors:  Puay-Wah Phuan; Baoxue Yang; John M Knapp; Alex B Wood; Gergely L Lukacs; Mark J Kurth; A S Verkman
Journal:  Mol Pharmacol       Date:  2011-07-05       Impact factor: 4.436

3.  Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.

Authors:  Darren M Hutt; Christian A Olsen; Chris J Vickers; David Herman; Monica Chalfant; Ana Montero; Luke J Leman; Renner Burkle; Bruce E Maryanoff; William E Balch; M Reza Ghadiri
Journal:  ACS Med Chem Lett       Date:  2011-07-21       Impact factor: 4.345

4.  Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein.

Authors:  John M Knapp; Alex B Wood; Puay-Wah Phuan; Michael W Lodewyk; Dean J Tantillo; A S Verkman; Mark J Kurth
Journal:  J Med Chem       Date:  2012-01-23       Impact factor: 7.446

5.  Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice.

Authors:  Holly R Davison; Stephanie Taylor; Chris Drake; Puay-Wah Phuan; Nico Derichs; Chenjuan Yao; Ella F Jones; Julie Sutcliffe; A S Verkman; Mark J Kurth
Journal:  Bioconjug Chem       Date:  2011-11-18       Impact factor: 4.774

Review 6.  CFTR: folding, misfolding and correcting the ΔF508 conformational defect.

Authors:  Gergely L Lukacs; A S Verkman
Journal:  Trends Mol Med       Date:  2011-12-03       Impact factor: 11.951

7.  Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin αvβ3.

Authors:  Long Ye; Tiffany Dickerson; Handeep Kaur; Yoko K Takada; Masaaki Fujita; Ruiwu Liu; John M Knapp; Kit S Lam; Neil E Schore; Mark J Kurth; Yoshikazu Takada
Journal:  Bioorg Med Chem Lett       Date:  2012-10-24       Impact factor: 2.823

Review 8.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

9.  Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.

Authors:  Michael B Donald; Kevin X Rodriguez; Hannah Shay; Puay-Wah Phuan; A S Verkman; Mark J Kurth
Journal:  Bioorg Med Chem       Date:  2012-07-06       Impact factor: 3.641

Review 10.  Cystic fibrosis transmembrane regulator correctors and potentiators.

Authors:  Steven M Rowe; Alan S Verkman
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.